重度哮喘免疫原性的最新进展：美泊利单抗的应用经验 - Suppr | 超能文献

相似文献

1

Update on immunogenicity in severe asthma: Experience with mepolizumab.重度哮喘免疫原性的最新进展：美泊利单抗的应用经验

J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2469-2475.e1. doi: 10.1016/j.jaip.2019.03.042. Epub 2019 Apr 5.

2

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.孟鲁司特钠联合布地奈德治疗儿童哮喘的临床疗效观察

J Allergy Clin Immunol. 2019 Nov;144(5):1336-1342.e7. doi: 10.1016/j.jaci.2019.08.005. Epub 2019 Aug 16.

3

Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.美泊利单抗治疗不适合使用奥马珠单抗的重度嗜酸性粒细胞性哮喘青少年：一个中心的早期临床经验

J Asthma. 2020 May;57(5):521-524. doi: 10.1080/02770903.2019.1579833. Epub 2019 Feb 22.

4

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.哮喘加重与严重嗜酸性粒细胞性哮喘患者肺功能下降相关。

J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):980-986.e1. doi: 10.1016/j.jaip.2017.12.019. Epub 2018 Feb 15.

5

Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis.抗嗜酸性粒细胞治疗与重度哮喘患者体重指数降低的关联：一项初步回顾性分析。

Ann Allergy Asthma Immunol. 2019 Jun;122(6):649-650. doi: 10.1016/j.anai.2019.03.031. Epub 2019 Apr 4.

6

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘患者期间的血液嗜酸性粒细胞表型

Allergol Int. 2024 Jul;73(3):473-476. doi: 10.1016/j.alit.2024.03.005. Epub 2024 Apr 6.

7

Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.按年龄和哮喘发病年龄划分的可接受美泊利珠单抗治疗的重度哮喘患者比例。

J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13.

8

Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：一位临床医生的治疗结果

Ann Allergy Asthma Immunol. 2018 Jul;121(1):121-123. doi: 10.1016/j.anai.2018.04.016. Epub 2018 Apr 21.

9

Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的效果与奥马珠单抗适应证的相关性。

Respir Med. 2019 Jul-Aug;154:69-75. doi: 10.1016/j.rmed.2019.06.004. Epub 2019 Jun 8.

10

Can sputum eosinophils predict a poor response to mepolizumab?痰液嗜酸性粒细胞能否预测对美泊利珠单抗反应不佳？

J Allergy Clin Immunol. 2024 Aug;154(2):280-281. doi: 10.1016/j.jaci.2024.04.013. Epub 2024 Apr 23.

引用本文的文献

1

Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.美泊利单抗和贝那利珠单抗靶向白细胞介素-5的比较见解：优化嗜酸性肉芽肿性多血管炎治疗策略

Biomolecules. 2025 Apr 8;15(4):544. doi: 10.3390/biom15040544.

2

Successful treatment with dupilumab in mepolizumab-resistant allergic bronchopulmonary aspergillosis.度普利尤单抗成功治疗对美泊利珠单抗耐药的变应性支气管肺曲霉病。

Respir Med Case Rep. 2023 Dec 16;47:101964. doi: 10.1016/j.rmcr.2023.101964. eCollection 2024.

3

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.